A Precision Mo₄VC₄‐Based Nanomedicine for Effective Cancer Elimination by Harnessing Senescence Induction and Immunogenic Response

Abstract Interest in therapies that influence cell senescence to regulate cancer cell is increasing. However, the understanding of the prolonged state of senescent cells and the interactions involved when utilizing therapies that promote senescence alongside other techniques to suppress cancer progression is limited. This study introduces an innovative artificial nanozyme named MVPR, constructed from vanadium MXene (Mo 4 VC 4 ) combined with the cyclin‐dependent kinase inhibitors Palbociclib and Arg‐Gly‐Asp, for the precise targeting of cancer cell membranes. Within the tumor environment, MVPR initiates a cascade of catalytic reactions, boosting glutathione consumption, generating reactive oxygen species (ROS). When the damage from ROS exceeds the cellular repair capabilities, the redox balance of tumor cells is disrupted, resulting in cell apoptosis. Alternatively, cancer cell senescence can be triggered under different circumstances. Senescent cancer cells impede their own and nearby cancer cell growth by releasing cytokines, thereby effectively curtail uncontrolled proliferation. Furthermore, the immune response triggered by senescent cell recruitment and the response evoked by metal ions in MVPR together enhance the immunotherapeutic effect, boosting immune system activity and augmenting CD4 + /CD8 + T cell proliferation. Cancer cells are effectively eliminated through the combined actions of pro‐senescence, enzyme catalysis, and immunogenic response. This study proposes a pro‐senescence strategy for anti‐tumor therapy.